Correction to “Efficacy and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort”

IF 5.1 2区医学 Q1 ONCOLOGY

Cancer Pub Date : 2026-03-13 DOI:10.1002/cncr.70342

引用次数: 0

Abstract

Martin TG, Mateos M-V, Yi JH, et al. Efficacy and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort. Cancer. 2026;e70237. doi:10.1002/cncr.70237

We apologize for these errors.

查看原文本刊更多论文

更正“teclistamab在三级暴露复发/难治性多发性骨髓瘤中的疗效和安全性：来自三个临床队列和一个回顾性队列的汇总结果”。

Martin TG, Mateos M-V，易建辉，等。特司他单抗治疗三级暴露复发/难治性多发性骨髓瘤的疗效和安全性：来自三个临床队列和一个回顾性队列的汇总结果癌症。2026;e70237。doi: 10.1002 / cncr。我们为这些错误道歉。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer 医学-肿瘤学

CiteScore

13.10

自引率

3.20%

发文量

480

审稿时长

2-3 weeks

期刊介绍： The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society. CANCER publishes interdisciplinary oncologic information according to, but not limited to, the following disease sites and disciplines: blood/bone marrow; breast disease; endocrine disorders; epidemiology; gastrointestinal tract; genitourinary disease; gynecologic oncology; head and neck disease; hepatobiliary tract; integrated medicine; lung disease; medical oncology; neuro-oncology; pathology radiation oncology; translational research